Forget the cure for cancer, heart disease, Alzheimer, or diabetes.

If you want a cure for cancer, heart disease, Alzheimer's and diabetes do not have the academic world, the National Institute of Health (NIH), or biotechnology and pharmaceutical industry. With all the money spent on research into these diseases, which have very little to show for it.

In 1971, during the State of the Union address, President Nixon declared war on cancer proposing "an intensive campaign to find a cure for cancer." From 1971, Americans spent, through taxes, donations and private R & D, about 200 billion U.S. dollars in dollars adjusted for inflation. This money produced 1.56 million documents on cancer. However, today we are no nearer a cure than we were in 1971. Why?

Consider what Dr. Almog said in his paper: Pharmaceutical Industry in the "depression" (Almog, D. Drug industry in "depression". Med Sci Monit. 2005 Jan; 11 (1): SR1-4 I urge you to read his paper, is a revelation about the relationship between academic research and commercial drug discovery): "When the basic science / biology of the disease is not available, no new drugs reach the market." With the billions of dollars spent by the NIH in basic science, and the millions of articles published on the subject, the question is, why is not the basic science and biology of the disease available? Individual discoveries in the biology of human diseases are a cornerstone of new treatments. However, drug discovery, these basic science / biology discoveries are seemingly unrelated items. To connect the dots we need a theory. The Blind Men and the Elephant is a famous story of six blind men find an elephant for the first time. Every man, taking advantage of the unique feature of the animal, which seemed to have touched first, and being unable to see everything, loudly maintained his limited views on the nature of the beast. The elephant was like a wall, a spear, a snake, a tree, a fan or a rope, depending on whether the blind had captured first part of the creature, tusk, trunk, knee, ear or tail. The story sums up the problem of the / b> approach in biology. Microcompetition A recent book by Foreign DNA and the Origin of Chronic Disease by Hanan Polansky [11], has an / b>. The book identifies the disturbance caused atherosclerosis, cancer, obesity, arthritis, diabetes type II alopecia, type I diabetes, multiple sclerosis, asthma, lupus, thyroiditis, inflammatory bowel disease, rheumatoid arthritis, psoriasis atopic dermatitis, graft versus host disease and other chronic diseases, and describes the sequence of events leading to the disruption of molecular effects, cellular and clinical. "

What are the consequences of failure of the NIH? A decrease in the number of new drugs introduced by pharmaceutical companies . Consider what Professor Taylor says in his paper: fewer new medicines in the pharmaceutical industry (D. Taylor fewer new drugs in the pharmaceutical industry. BMJ. 2003 February 22, 326 (7386) :408-9): "In 2002 spending on medicines exceeded $ 400bn (248bn ฃ; 377bn) worldwide. optimists in the pharmaceutical industry believes that the global market for their products will be on expansion of around 10% per year, with the United States continues leading to higher per capita costs. Expenses of research by the pharmaceutical industry is also increasing worldwide. For more than 45 billion $ per year --- twice the amount recorded at the beginning of the 1990s --- and is projected to increase to $ 55 billion by 2005-6. The concern, however, on the productivity of research funded by large pharmaceutical companies. ... The empirical evidence indicates a crisis of productivity in pharmaceutical research. The number of drugs introduced worldwide that contain new active substances are reduced from an average of more than 60 years in the late 1980s to 52 in 1991 and only 31 in 2001. The total number of new active ingredients under a review of the regulation continues to fall. "

On the one hand, research spending is increasing. In . The professionals call this situation, the crisis of productivity in drug discovery.

The NIH could not produce the biology, so necessary for chronic diseases because it is trapped in the reductionist mentality. Dr. Hanan Polansky offers an alternative. If we want a cure for cancer, heart disease, Alzheimer's and diabetes, we must seriously consider the alternative.